利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.014 秒)

    Method of classifying gene expression strength in lung cancer tissues
    12.
    发明公开
    Method of classifying gene expression strength in lung cancer tissues 有权
    Verfahren zur Klassifizierung der Genexpressions-Stärkein Lungenkrebsgeweben。

    公开(公告)号：EP2295605A1

    公开(公告)日：2011-03-16

    申请号：EP10182585.9

    申请日：2004-12-10

    申请人： Aichi Prefecture ,  FUJIFILM Corporation

    发明人： Takahashi, Takashi ,  Tomita, Shuta ,  Mitsudomi, Tetsuya ,  Yatabe, Yasushi ,  Ogura, Nobuhiko ,  Some, Masato

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158

    摘要： The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method.
    A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene selected from the group consisting of
    in lung cancer tissues isolated from the patient.

    摘要翻译： 本发明提供一种确认基因表达的方法，其用于决定患有肺癌的五年存活率和该方法中使用DNA探针试剂盒。 一种用于决定非小细胞肺癌患者的存活率的方法，其包括确认从患者分离的肺癌组织中选出的至少一种基因的表达强度。

    METHOD OF SCREENING FOR CANCER AND ADENOMA
    14.
    发明公开
    METHOD OF SCREENING FOR CANCER AND ADENOMA 有权
    SCREENING-VERFAHRENFÜRKREBS UND ADENOM

    公开(公告)号：EP1865325A1

    公开(公告)日：2007-12-12

    申请号：EP05816850.1

    申请日：2005-12-15

    申请人： Japan Science and Technology Agency ,  Local Gavernment of Aichi Prefecture

    发明人： KANNAGI, Reiji ,  IZAWA, Mineko ,  KIMURA, Naoko ,  KUREI, Shunsuke ,  WATANABE, Kazue

    IPC分类号： G01N33/574 ,  C07K16/30

    CPC分类号： C07K16/40 ,  C07K16/3076 ,  G01N33/57407 ,  G01N2333/91194 ,  G01N2400/02

    摘要： [PROBLEMS] To provide examination methods and reagents able to detect efficiently cancer patients and patients at high risk of cancer.
    [MEANS FOR SOLVING PROBLEMS] Significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, between non-carcinoma tissues and carcinoma tissues or adenoma tissues were discovered. The discovery is evidently applicable to detect carcinomas and adenomas (except colorectal carcinomas and colorectal adenomas) specifically by assaying a certain range of GlcNAc-6-sulfated sugar residue groups in tissues of patients and in fecal samples. Examination of carcinomas and adenomas is possible by the use of antibodies reacting specifically with GlcNAc-6-sulfated sugar residues specifically synthesized by enzymes present in carcinoma and adenoma tissues.

    摘要翻译： [问题]提供能够有效检测癌症患者和癌症高危患者的检查方法和试剂。 [解决问题的方法]发现了GlcNAc-6-磺基转移酶同工酶，糖残基硫酸化酶，非癌组织和癌组织或腺瘤组织分布的显着差异。 该发现显然适用于通过测定患者组织和粪便样品中特定范围的GlcNAc-6硫酸化糖残基来检测癌和腺瘤（结肠直肠癌和结肠直肠腺瘤除外）。 可以通过使用特异性地与存在于癌和腺瘤组织中的酶特异性合成的GlcNAc-6硫酸化糖残基的抗体来检查癌和腺瘤。

    Method of classifying gene expression strength in lung cancer tissues
    15.
    发明公开
    Method of classifying gene expression strength in lung cancer tissues 有权
    肺癌组织中基因表达强度的分类方法

    公开(公告)号：EP1795615A2

    公开(公告)日：2007-06-13

    申请号：EP07006700.4

    申请日：2004-12-10

    申请人： Aichi Prefecture ,  FUJIFILM Corporation

    发明人： Takahashi, Takashi ,  Tomita, Shuta ,  Mitsudomi, Tetsuya ,  Yatabe, Yasushi ,  Ogura, Nobuhiko ,  Some, Masato

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158

    摘要： The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method.
    A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene selected from the group consisting of in lung cancer tissues isolated from the patient.

    摘要翻译： 本发明提供了确定基因表达的方法，用于确定患有肺癌的患者的五年存活率以及在该方法中使用DNA探针试剂盒。 一种用于确定非小细胞肺癌患者存活率的方法，包括确认选自由患者分离的肺癌组织中的至少一种基因的表达强度。

    METHOD OF EXAMINING COLON CANCER AND COLON ADENOMA
    17.
    发明公开
    METHOD OF EXAMINING COLON CANCER AND COLON ADENOMA 有权
    VERFAHREN ZUR UNTERSUCHUNG VON KOLONKARZINOM UND KOLONADENOM

    公开(公告)号：EP1674869A1

    公开(公告)日：2006-06-28

    申请号：EP04747273.3

    申请日：2004-07-09

    申请人： Japan Science and Technology Agency ,  Local Gavernment of Aichi Prefecture ,  Wako Pure Chemical Industries, Ltd.

    发明人： KANNAGI, Reiji ,  IZAWA, Mineko ,  MURAMATSU, Takashi, 5, Hirabari-Jyutaku ,  UCHIMURA, Kenji ,  HOSOKAWA, Hideaki

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57419 ,  G01N2333/91097 ,  G01N2400/02

    摘要： The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc -6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas.

    摘要翻译： 本发明提供一种检查结肠直肠癌和结肠直肠腺瘤的方法，其能够以高概率检测结肠直肠癌患者和高结肠直肠癌风险的患者，并且可用于诊断结肠直肠癌和结肠直肠腺瘤，并提供检查试剂 它们。 本发明人发现，GlcNAc-6-磺基转移酶同工酶，糖残基的硫酸化酶在非癌结肠直肠组织，结肠直肠癌组织和结肠直肠腺瘤组织中的分布存在显着差异。 此外，本发明人将该发现应用于诊断，并发现通过测定来自患者或粪便样品的组织中GlcNAc -6-硫酸化糖残基的确定范围来特异性检测结肠直肠癌和腺瘤。 与存在于结肠直肠癌和结肠直肠腺瘤组织中的酶特异性产生的GlcNAc-6硫酸化糖残基反应的MECA-79抗体（Pharmingen，目录号09961D，经销商：Becton Dickinson）可用于检查 结肠直肠癌和结直肠腺瘤。

    Method of classifying gene expression strength in lung cancer tissues
    18.
    发明公开
    Method of classifying gene expression strength in lung cancer tissues 有权
    VERFAHREN ZUR KLASSIFIZIERUNG DER GENEXPRESSIONS-STÄRKE在LUNGENKREBSGEWEBEN。

    公开(公告)号：EP1541698A2

    公开(公告)日：2005-06-15

    申请号：EP04029389.6

    申请日：2004-12-10

    申请人： Aichi Prefecture ,  Fuji Photo Film Co., Ltd.

    发明人： Takahashi, Takashi ,  Tomita, Shuta ,  Mitsudomi, Tetsuya ,  Yatabe, Yasushi ,  Ogura, Nobuhiko ,  Some, Masato

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158

    摘要： The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method.
    A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene selected from the group consisting of in lung cancer tissues isolated from the patient.

    摘要翻译： 本发明提供一种确认基因表达的方法，其用于决定患有肺癌的五年存活率和该方法中使用DNA探针试剂盒。 一种用于决定非小细胞肺癌患者的存活率的方法，包括确认选自患者分离的肺癌组织中的至少一种基因的表达强度。

    CHIMERIC CYTOKINE RECEPTOR
    19.
    发明公开
    CHIMERIC CYTOKINE RECEPTOR 审中-实审

    公开(公告)号：EP4365295A1

    公开(公告)日：2024-05-08

    申请号：EP22832556.9

    申请日：2022-03-31

    申请人： Aichi Prefecture

    发明人： KAGOYA, Yuki ,  YOSHIKAWA, Toshiaki

    IPC分类号： C12N15/62 ,  A61K35/15 ,  A61K35/17 ,  A61P35/00 ,  C07K14/715 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/0786 ,  C12N5/10 ,  C12N15/12 ,  C12N15/63

    CPC分类号： A61P35/00 ,  C07K14/435 ,  C07K14/715 ,  C07K19/00 ,  C12N5/06 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  A61K39/4631 ,  A61K39/4611 ,  A61K39/464419 ,  A61K39/464412 ,  A61K39/464468 ,  A61K2239/4820230501 ,  A61K39/464471

    摘要： To achieve both of improvement of therapeutic efficacy and reduction of side effects in adoptive immunotherapy, the present invention provides a novel technique for enhancing functions such as proliferation ability and imparting an activity of capturing cytokines which may cause side effects in immune cells for use in the adoptive immunotherapy. Provided is a chimeric cytokine receptor comprising a ligand-binding region at the N-terminal side and a T-cell activating region at the C-terminal side, wherein: said ligand-binding region consists of a cytokine-binding region of a cytokine receptor, said T-cell activating region comprises the transmembrane domain and the intracellular domain of an IL-7 (Interleukin-7) receptor α chain, and said transmembrane domain has an insertion of any one selected from the group consisting of (a) the amino acid sequence of SEQ ID NO: 2 between position 243 and position 244 in the amino acid sequence of SEQ ID NO: 1, (b) the amino acid sequence of SEQ ID NO: 3 between position 241 and position 242 in the amino acid sequence of SEQ ID NO: 1, (c) the amino acid sequence of SEQ ID NO: 4 between position 244 and position 245 in the amino acid sequence of SEQ ID NO: 1, (d) the amino acid sequence of SEQ ID NO: 5 between position 244 and position 245 in the amino acid sequence of SEQ ID NO: 1, and (e) the amino acid sequence of SEQ ID NO: 6 between position 246 and position 247 in the amino acid sequence of SEQ ID NO: 1.